623
Views
13
CrossRef citations to date
0
Altmetric
Meeting Report

American Society of Clinical Oncology 2010 colorectal update

&
Pages 1371-1373 | Published online: 10 Jan 2014

References

  • Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer Statistics, 2007. CA Cancer J. Clin.57, 43–66 (2007).
  • Alberts SR, Sargent DJ, Smyrk TC et al. Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): results from NCCTG Intergroup Phase III Trial N0147. J. Clin. Oncol.28(18 Suppl.) (2010) (Abstract CRA3507).
  • Goldberg RM, Sargent DJ, Thibodeau SN et al. Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with KRAS mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup Phase III Trial N0147. J. Clin. Oncol.28(15 Suppl.) (2010) (Abstract 3508).
  • Maughan TS, Adams R, Smith CG et al.; MRC COIN Trial Investigators. Identification of potentially responsive subsets when cetuximab is added to oxaliplatin–fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): mature results of the MRC COIN trial. J. Clin. Oncol.28(15 Suppl.) (2010) (Abstract 3502).
  • Tabernero J, Aranda E, Gomez A et al. Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): the MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]). J. Clin. Oncol.28(15 Suppl.) (2010) (Abstract 3501).
  • McCahill LE, Yothers GA, Sharif S et al. A Phase II trial of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab (Bev) for patients (pts) with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: results of NSABP C-10. J. Clin. Oncol.28(15 Suppl.) (2010) (Abstract 3527).
  • Ngan S, Fisher R, Goldstein D et al. A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: an intergroup trial (TROG, AGITG, CSSANZ, RACS). J. Clin. Oncol.28(15 Suppl.) (2010) (Abstract 3509).
  • Schrag D, Weiser MR, Goodman KA et al. Neoadjuvant FOLFOX–Bev, without radiation, for locally advanced rectal cancer. J. Clin. Oncol.28(15 Suppl.) (2010) (Abstract 3511).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.